KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 07/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -337.21% | -- | -- | -15.93% | -6.86% |
| Total Depreciation and Amortization | -39.47% | -- | -- | 0.40% | 9.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.37% | -- | -- | 285.01% | -73.93% |
| Change in Net Operating Assets | 67.76% | -- | -- | -433.26% | -74.79% |
| Cash from Operations | -417.45% | -- | -- | -14.58% | -45.55% |
| Capital Expenditure | 82.65% | -- | -- | -0.69% | -1,100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -108.80% | -- | -- | 728.31% | -140.16% |
| Cash from Investing | -111.05% | -- | -- | 671.84% | -143.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -42.02% | -96.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.16% | -- | -- | 944.08% | -98.54% |
| Foreign Exchange rate Adjustments | 75.21% | -- | -- | 21.56% | 279.34% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -118.22% | -- | -- | 84.39% | -137.05% |